Madrigal Pharmaceuticals Stock Price Prediction
| MDGL Stock | USD 495.12 1.42 0.29% |
Momentum 36
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (1.87) | EPS Estimate Current Year (10.86) | EPS Estimate Next Year 1.6898 | Wall Street Target Price 657.1333 | EPS Estimate Current Quarter (1.99) |
Using Madrigal Pharmaceuticals hype-based prediction, you can estimate the value of Madrigal Pharmaceuticals from the perspective of Madrigal Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Madrigal Pharmaceuticals using Madrigal Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Madrigal using crowd psychology based on the activity and movement of Madrigal Pharmaceuticals' stock price.
Madrigal Pharmaceuticals Short Interest
An investor who is long Madrigal Pharmaceuticals may also wish to track short interest. As short interest increases, investors should be becoming more worried about Madrigal Pharmaceuticals and may potentially protect profits, hedge Madrigal Pharmaceuticals with its derivative instruments, or be ready for some potential downside.
200 Day MA 407.4175 | Short Percent 0.1887 | Short Ratio 13.37 | Shares Short Prior Month 3.7 M | 50 Day MA 554.8082 |
Madrigal Pharmaceuticals Hype to Price Pattern
Investor biases related to Madrigal Pharmaceuticals' public news can be used to forecast risks associated with an investment in Madrigal. The trend in average sentiment can be used to explain how an investor holding Madrigal can time the market purely based on public headlines and social activities around Madrigal Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Madrigal Pharmaceuticals' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals Implied Volatility | 0.56 |
Madrigal Pharmaceuticals' implied volatility exposes the market's sentiment of Madrigal Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Madrigal Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Madrigal Pharmaceuticals stock will not fluctuate a lot when Madrigal Pharmaceuticals' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Madrigal Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Madrigal because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Madrigal Pharmaceuticals after-hype prediction price | USD 492.56 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Madrigal contract
Based on the Rule 16, the options market is currently suggesting that Madrigal Pharmaceuticals will have an average daily up or down price movement of about 0.035% per day over the life of the 2026-04-17 option contract. With Madrigal Pharmaceuticals trading at USD 495.12, that is roughly USD 0.17 . If you think that the market is fully incorporating Madrigal Pharmaceuticals' daily price movement you should consider acquiring Madrigal Pharmaceuticals options at the current volatility level of 0.56%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Madrigal Pharmaceuticals Basic Forecasting Models to cross-verify your projections. Madrigal Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of Madrigal Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Madrigal Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Madrigal Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Madrigal Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Madrigal Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Madrigal Pharmaceuticals' historical news coverage. Madrigal Pharmaceuticals' after-hype downside and upside margins for the prediction period are 489.47 and 495.65, respectively. We have considered Madrigal Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Madrigal Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Madrigal Pharmaceuticals is based on 3 months time horizon.
Madrigal Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Madrigal Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Madrigal Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Madrigal Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.31 | 3.09 | 0.08 | 0.04 | 14 Events / Month | 7 Events / Month | In about 14 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
495.12 | 492.56 | 0.02 |
|
Madrigal Pharmaceuticals Hype Timeline
Madrigal Pharmaceuticals is now traded for 495.12. The entity has historical hype elasticity of 0.08, and average elasticity to hype of competition of -0.04. Madrigal is forecasted to increase in value after the next headline, with the price projected to jump to 492.56 or above. The average volatility of media hype impact on the company the price is over 100%. The price upswing on the next news is projected to be 0.02%, whereas the daily expected return is now at 0.31%. The volatility of related hype on Madrigal Pharmaceuticals is about 2223.02%, with the expected price after the next announcement by competition of 495.08. The company reported the previous year's revenue of 180.13 M. Net Loss for the year was (465.89 M) with profit before overhead, payroll, taxes, and interest of 705.49 M. Given the investment horizon of 90 days the next forecasted press release will be in about 14 days. Check out Madrigal Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Madrigal Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Madrigal Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Madrigal Pharmaceuticals' future price movements. Getting to know how Madrigal Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Madrigal Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| RNA | Avidity Biosciences | 0.04 | 12 per month | 0.00 | 0.12 | 0.91 | (0.34) | 42.94 | |
| JAZZ | Jazz Pharmaceuticals PLC | 1.68 | 8 per month | 1.70 | 0.08 | 3.66 | (3.14) | 25.96 | |
| MRNA | Moderna | 6.31 | 7 per month | 3.82 | 0.17 | 10.85 | (7.01) | 23.11 | |
| CAI | Caris Life Sciences | (0.48) | 10 per month | 0.00 | (0.08) | 4.33 | (4.27) | 21.66 | |
| RYTM | Rhythm Pharmaceuticals | (5.21) | 10 per month | 0.00 | (0.04) | 4.03 | (5.14) | 18.69 | |
| ABVX | Abivax SA American | (2.80) | 8 per month | 3.44 | 0.08 | 6.94 | (6.09) | 29.38 | |
| TECH | Bio Techne Corp | (0.10) | 6 per month | 1.75 | (0.03) | 3.72 | (2.93) | 8.09 | |
| EXEL | Exelixis | 0.95 | 10 per month | 1.72 | 0.06 | 4.06 | (2.93) | 11.45 | |
| BMRN | Biomarin Pharmaceutical | (1.16) | 11 per month | 1.71 | 0.01 | 3.20 | (3.05) | 22.06 | |
| BAX | Baxter International | (0.62) | 9 per month | 0.00 | (0.11) | 2.82 | (3.63) | 15.20 |
Madrigal Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Madrigal price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Madrigal using various technical indicators. When you analyze Madrigal charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Madrigal Pharmaceuticals Predictive Indicators
The successful prediction of Madrigal Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Madrigal Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Madrigal Pharmaceuticals based on analysis of Madrigal Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Madrigal Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Madrigal Pharmaceuticals's related companies. | 2025 | 2026 (projected) | Dividend Yield | 0.008267 | 0.007348 | Price To Sales Ratio | 41.91 | 39.81 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Madrigal Pharmaceuticals Basic Forecasting Models to cross-verify your projections. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. Expected growth trajectory for Madrigal significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Madrigal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (12.91) | Revenue Per Share | Quarterly Revenue Growth 3.62 | Return On Assets | Return On Equity |
Investors evaluate Madrigal Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Madrigal Pharmaceuticals' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Madrigal Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Madrigal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Madrigal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Madrigal Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.